Nothing Special   »   [go: up one dir, main page]

BR0215193A - Formulações de azitromicina diretamente compressìveis - Google Patents

Formulações de azitromicina diretamente compressìveis

Info

Publication number
BR0215193A
BR0215193A BR0215193-6A BR0215193A BR0215193A BR 0215193 A BR0215193 A BR 0215193A BR 0215193 A BR0215193 A BR 0215193A BR 0215193 A BR0215193 A BR 0215193A
Authority
BR
Brazil
Prior art keywords
azithromycin
tablet
mga
pharmaceutically acceptable
acceptable excipient
Prior art date
Application number
BR0215193-6A
Other languages
English (en)
Inventor
Brendn John Murphy
Steven William Collier
Ernest Shing Quan
Barbara Alice Johnson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0215193A publication Critical patent/BR0215193A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES DE AZITROMICINA DIRETAMENTE COMPRESSìVEIS". A presente invenção refere-se a uma mistura seca, usada para formar comprimidos de azitromicina por compressão direta, compreendendo azitromicina não-diidrato e pelo menos um excipiente farmaceuticamente aceitável. Esta invenção refere-se também a um comprimido de azitromicina compreendendo azitromicina não-diidratada e pelo menos um excipiente farmaceuticamente aceitável. Preferencialmente, o comprimido de azitromicina é formado por compressão direta da mistura seca, da presente invenção, para formar o referido comprimido de azitromicina. Preferencialmente, o comprimido de azitromicina, da presente invenção, contém uma dosagem de 250 mgA, 500 mgA e 600 mgA. Esta invenção refere-se ainda a um comprimido de azitromicina que é produzido formando uma mistura seca de uma azitromicina não granulada de forma A e pelo menos um excipiente farmaceuticamente aceitável. O comprimido de azitromicina é então formado por compressão direta da mistura seca.
BR0215193-6A 2001-12-21 2002-12-09 Formulações de azitromicina diretamente compressìveis BR0215193A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21
PCT/IB2002/005222 WO2003053416A1 (en) 2001-12-21 2002-12-09 Directly compressible formulations of azithromycin

Publications (1)

Publication Number Publication Date
BR0215193A true BR0215193A (pt) 2004-11-16

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215193-6A BR0215193A (pt) 2001-12-21 2002-12-09 Formulações de azitromicina diretamente compressìveis

Country Status (20)

Country Link
US (4) US20030165563A1 (pt)
EP (1) EP1455758A1 (pt)
JP (1) JP2005513099A (pt)
KR (1) KR100632339B1 (pt)
CN (1) CN1668282A (pt)
AR (1) AR037930A1 (pt)
AU (1) AU2002348884A1 (pt)
BR (1) BR0215193A (pt)
CA (1) CA2469246A1 (pt)
IL (1) IL161996A0 (pt)
MX (1) MXPA04005105A (pt)
NO (1) NO20043110L (pt)
NZ (1) NZ532707A (pt)
PA (1) PA8562201A1 (pt)
PE (1) PE20030591A1 (pt)
PL (1) PL371259A1 (pt)
RU (1) RU2277914C2 (pt)
TW (1) TW200301138A (pt)
WO (1) WO2003053416A1 (pt)
ZA (1) ZA200403486B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
WO2005002592A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
CA2547597A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
EP1691787B1 (en) 2003-12-04 2008-07-02 Pfizer Products Inc. Method for making pharmaceutical multiparticulates
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20100048498A1 (en) * 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
AU2007335155A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc A composition containing a bisphosphonic acid in combination with vitamin D
CA2694516A1 (en) * 2007-07-31 2009-02-05 Cargill, Incorporated Direct compressible dextrose
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
US20110033526A1 (en) * 2008-03-18 2011-02-10 Aleksander Vladimirovich Dikovskiy Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy
EP2266582B1 (en) * 2008-03-18 2015-04-29 Dikovskiy, Aleksander Vladimirovich Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
WO2015127471A1 (en) 2014-02-24 2015-08-27 Mindojo Ltd. E-learning datagraph structures
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (pt) * 1992-07-30 1996-03-01 Pfizer
EP0758549A4 (en) * 1994-04-26 1997-07-02 Nobuhiro Narita MEDICAL COMPOSITION AS A MEDICINE FOR NON-SMALL CELL CANCER
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CA2189658C (en) * 1994-05-06 2000-10-31 William J. Curatolo Controlled-release dosage forms of azithromycin
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
WO1999012552A1 (en) * 1997-09-10 1999-03-18 Merck & Co., Inc. 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
ATE279200T1 (de) * 1998-11-30 2004-10-15 Teva Pharma Ethanolate des azithromycin, herstllungsverfahren und deren pharmazeutische zusammenstellungen
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
BR0209918A (pt) * 2001-05-22 2004-03-30 Pfizer Prod Inc Formas cristalinas da azitromicina
PT1446010E (pt) * 2001-10-18 2009-06-08 Teva Pharma Composições de azitromicina estabilizadas
WO2003053399A2 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
KR100676025B1 (ko) * 2002-02-01 2007-01-29 화이자 프로덕츠 인코포레이티드 아지쓰로마이신의 건조 과립화 제제

Also Published As

Publication number Publication date
RU2004118709A (ru) 2005-04-20
PE20030591A1 (es) 2003-07-12
NO20043110L (no) 2004-07-20
PL371259A1 (en) 2005-06-13
WO2003053416A1 (en) 2003-07-03
US7070811B2 (en) 2006-07-04
TW200301138A (en) 2003-07-01
KR20040066175A (ko) 2004-07-23
US20060024363A1 (en) 2006-02-02
RU2277914C2 (ru) 2006-06-20
AR037930A1 (es) 2004-12-22
IL161996A0 (en) 2005-11-20
NZ532707A (en) 2006-07-28
AU2002348884A1 (en) 2003-07-09
KR100632339B1 (ko) 2006-10-12
JP2005513099A (ja) 2005-05-12
US20050287209A1 (en) 2005-12-29
US20030165563A1 (en) 2003-09-04
ZA200403486B (en) 2006-05-31
PA8562201A1 (es) 2003-07-28
CA2469246A1 (en) 2003-07-03
MXPA04005105A (es) 2004-08-19
EP1455758A1 (en) 2004-09-15
CN1668282A (zh) 2005-09-14
US20060024364A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR0213288A (pt) Etilcelulose altamente compressìvel para formação de comprimidos
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BR0111186A (pt) Uso de composição de celecoxib para rápido alìvio de dor
TW200716208A (en) Modified and immediate release memantine bead formulation
HN2001000012A (es) Tratamiento de la enfermedad neurodegenerativa
WO2007016563A3 (en) Alcohol resistant pharmaceutical formulations
TR200002207T1 (tr) Slekoksib bileşikleri.
ES2187822T3 (es) Comprimidos de disgregacion rapida.
HK1077208A1 (en) Topical composition containing at least one vitminD or one vitamin D analogue and at least one cort icosteroid
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
BR0015188A (pt) Composições farmacêuticas
ES2152966T3 (es) Formas de dosificado farmaceuticas de desleido rapido y procedimiento para su preparacion.
BR0211972A (pt) Composição oftálmica
HK1076605A1 (en) Formulations
MXPA03010549A (es) Formas de dosificacion de oxcarbazepina.
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
GB0012362D0 (en) Chemical compounds
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 9/20; A61K 31/7052; A61P 31/00

Ipc: A61K 9/20 (2011.01), A61K 31/7052 (2011.01), A61P

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.